Increasing Prevalence of Chronic Disorders Fuels North America Prefilled Syringe Market
The growing aging population and changes in social behavior and lifestyle contribute to some of the common long-term health conditions. As per the World Health Organization (WHO), the prevalence of chronic lifestyle diseases is expected to increase by 57% by the end of 2026. The emerging markets will be hit hardest, as a population explosion is expected in developing countries. With the increasing urbanization, people are more inclined toward a sedentary lifestyle, which results in rheumatoid arthritis, diabetes, and others. Diabetes is one of the major global health issues of the 21st century. According to the International Diabetes Federation (IDF), the number of people with diabetes in North America was about 46 million in 2019 and is projected to reach 62 million by 2045. The increase in disease prevalence is approximated to be 35% during the projection period.Other chronic conditions such as Crohn's disease, multiple sclerosis, and cardiovascular disorders require frequent drug administration for disease management and treatment. As per the WHO, cardiovascular disorders are the leading cause of death-nearly 17.9 million deaths are reported every year due to cardiovascular disorders. It has become a new standard for injectable drug delivery among large patient populations globally. Moreover, these prefilled syringes can be used by a large patient population with minimal training and do not require constant assistance from healthcare professionals, owing to which prefilled syringes are adopted largely in professional healthcare environments as well as home healthcare settings, thereby driving the prefilled syringes market growth.
North America Prefilled Syringe Market Overview
The North America prefilled syringes market is segmented into the US, Canada, and Mexico. The growth of the prefilled syringes market in the region is mainly due to the increased adoption of self-injecting parenteral devices and a surge in home healthcare to treat chronic diseases in the region.According to the Diabetes Research Institute, the number of people with diabetes in the US was ~37.3 million (11.3% of the population) in 2022. Nearly 28.7 million people in the US were diagnosed with diabetes, and approximately 8.6 million people have undiagnosed diabetes. Further, ~1.4 million diabetes cases are diagnosed each year in the US. According to the Centers for Disease Control and Prevention, in 2020, ~88 million adults had prediabetes, which is 34.5% of the US adult population. According to Yale researchers, in 2022, ~30 million people in the US have diabetes, and about 7 million require daily insulin.
There is an increase in the demand for infertility treatment in the US. According to the CDC, in 2022, ~22% married couples, with women aged above 30 years, have problems in conceiving their first child. To overcome with infertility issues, various treatments are available in the market through prefilled syringes. In July 2023, Fresenius Kabi launched Ganirelix Acetate Injection, a generic fertility drug, in 250 mcg0.5 ml prefilled syringes as part of the company's expansion in women's health. Therefore, the increasing prevalence of diabetes and other disorders, along with surge in product launches, is expected to drive the growth of prefilled syringes market in the US.
North America Prefilled Syringe Market Segmentation
The North America prefilled syringe market is segmented based on type, material, design, application, distribution channel, and country.Based on type, the North America prefilled syringe market is bifurcated into disposable prefilled syringes and reusable prefilled syringes. The disposable prefilled syringes segment held a larger North America prefilled syringe market share in 2022.
Based on material, the North America prefilled syringe market is bifurcated into glass prefilled syringes and plastic prefilled syringes. The glass prefilled syringes segment held a larger North America prefilled syringe share in 2022.
Based on designs, the North America prefilled syringe market is bifurcated into single chamber and multi chamber. The single chamber segment held a larger North America prefilled syringe share in 2022.
In terms of application, the North America prefilled syringe market is segmented into cancer, diabetes, autoimmune disease, infectious diseases, and others. The others segment held the largest North America prefilled syringe share in 2022.
By distribution channel, the North America prefilled syringe market is segmented into hospital pharmacy, retail pharmacy, and online channel. The hospital pharmacy segment held the largest North America prefilled syringe market share in 2022.
Based on country, the North America prefilled syringe market is categorized into the US, Canada, and Mexico. The US dominated the North America prefilled syringe market in 2022.
B Braun SE, Shandong Weigao Group Medical Polymer Co Ltd, Gerresheimer AG, Schott AG, Nipro Corp, Becton Dickinson and Co, Baxter International Inc, Terumo Corp, and Ypsomed Holding AG are some of the leading companies operating in the North America prefilled syringe market.
Table of Contents
Companies Mentioned
- B Braun SE
- Baxter International Inc
- Becton Dickinson and Co
- Gerresheimer AG
- Nipro Corp
- Schott AG
- Shandong Weigao Group Medical Polymer Co Ltd
- Terumo Corp
- Ypsomed Holding AG